The observation that levels of the mitogenic peptide endothelin-1 are elevated in the human coronary sinus after percutaneous transluminal coronary angioplasty (PTCA) has implicated endothelin-1 in the etiology of vascular restenosis. The present study examined this hypothesis in both an in vitro and an in vivo rat model of neointimal formation by using the novel nonpeptide endothelin receptor antagonist SB 209670. In vitro, endothelin-1 (1 nmol/L) induced a ninefold increase in rat
aortic vascular smooth muscle [3Hlthymidine incorporation. This endothelin A receptor-mediated effect was completely inhibited by SB 209670 (IC50, 6 .2±2.2 nmol/L). In vivo, acute intra-arterial administration of exogenous endothelin-1 (5 to 500 pmol/kg over a 30-minute period immediately after angioplasty) dose-dependently augmented the degree of neointimal formation (by up to 150% when assessed 14 days after surgery). This response was evident as early as 7 days after angioplasty. Hemodynamic studies indicated that this action was unrelated to a systemic pressor action of the peptide. Administration of SB 209670 (2.5 mg/kg IP, twice a day for 3 days before and for 2 weeks after surgery) reduced neointimal formation by '50% relative to control animals. Thus, the data indicate for the first time that (1) endothelin-1 promotes neointimal formation in vivo and (2) endogenous endothelin-1 is involved in the pathogenesis of angioplasty-induced lesion formation in the rat. Endothelin receptor antagonists such as SB 209670 may therefore serve as useful adjuncts to PTCA, attenuating the degree of vascular restenosis observed after vascular wall injury. (Circ Res. 1994; 75:190-197.) Key Words * balloon angioplasty * endothelin receptor antagonist * SB 209670 * endothelin-1 * neointimal formation T he major factor limiting the long-term efficacy of percutaneous transluminal coronary angioplasty (FTCA) is the high incidence of neointimal formation and subsequent vascular restenosis. The advanced occlusive atherosclerotic lesions observed in humans are characterized by a marked fibroproliferative response involving large numbers of intimal smooth muscle cells, macrophages, and T lymphocytes.1 Several neurohumoral factors, such as angiotensin II and norepinephrine, have been implicated in neointimal development.2 Like angiotensin II and norepinephrine, endothelin-1 is now recognized as playing an intrinsic role in the endogenous control of systemic hemodynamics. 3 Since levels of endothelin-1 are elevated in the human coronary sinus after PTCA, it has been suggested that endothelin-1 is involved in the pathogenesis of vascular restenosis. 4 In addition to its actions on vascular smooth muscle tonus, endothelin-1 is also a potent mitogen in several cultured cell lines of both cardiovascular and noncar-growth factors, the latter of which may be synergistic. [6] [7] [8] [9] [10] However, despite these in vitro observations, the in vivo role of endothelin-1 as a mitogen is unknown, since results from cell culture are often difficult to interpret (eg, because of the absence of blood-borne factors and interactions between different cell types) and may not translate into an in vivo situation. Therefore, the present study was designed to assess the effects of acute exogenous endothelin-1 administration on the degree of neointimal formation observed after rat carotid artery balloon angioplasty. To examine the role of endogenous endothelin-1 in neointimal formation, the antiproliferative effects of the novel nonpeptide endothelin receptor antagonist SB 209670 were assessed both in vitro and in the rat carotid artery balloon angioplasty model. SB 209670 exhibits extremely high affinity for human cloned endothelin A (ETA) and endothelin B (ETB) receptors (Kis of 0.2 and 18 nmol/L, respectively) and competitively inhibits both ETA-and ETB-mediated contractions in isolated rat aortas and rabbit pulmonary arteries (Kbs of 0.4 and 50 nmol/L, respectively). '1 Materials and Methods
Rat Aortic Vascular Smooth Muscle Cultures and [3H]Thymidine Incorporation Assay
Thoracic aortas of male Sprague-Dawley rats (300 g, Charles River Laboratories) were excised, cleaned of adherent tissue, and immersed in Dulbecco's modified essential medium (DMEM, GIBCO) containing gentamicin (50 gg/mL). Vascular smooth muscle cells were allowed to grow out from the explants as described previously.5 After confluence was reached, cells were harvested by brief exposure to trypsin and grown in T-150 flasks. All cells used for experimentation were early subculture (104 cells per square centimeter in 24-well plates, between passages 2 and 4). Confluent smooth muscle cells were quiesced by substituting the culture medium with DMEM containing insulin (5 ,ug/mL), transferrin (5 ,ug/mL), and sodium selenite (5 ng/mL) for 2 days. The medium was replenished once during and once after this quiescence period. Endothelin-1 (a submaximal concentration of 1 nmol/L, previously determined as being equivalent to the EC75 concentration for peptide-induced [3H]thymidine incorporation) was added to the culture medium in the presence or absence of SB 209670 (0.1 to 100 nmol/L) for an additional 24-hour period.5 DNA synthesis was assessed by measuring the degree of [3H]thymidine incorporation into the trichloroacetic acidinsoluble cellular fraction over the final 4 hours of this incubation period (triplicate determinations).
Rat Left Common Carotid Artery

Balloon Angioplasty
Left common carotid artery balloon angioplasty was performed under aseptic conditions on male Sprague-Dawley rats (350 to 400 g) under sodium pentobarbital anesthesia (65 mg/kg IP, Steris Laboratories) as described previously. 12 Briefly, after a midline incision, the left external carotid artery was identified and cleared of adherent tissue, allowing the insertion of a 2F Fogarty arterial embolectomy catheter (model 12-060-2F, Baxter Healthcare). The catheter was guided a fixed distance down the common carotid artery to the aortic arch, inflated with a fixed volume of fluid, and withdrawn back to the site of insertion. This procedure was performed a total of three times, and once complete, the catheter was removed.
Administration of Exogenous Endothelin-1
After Angioplasty
A length of PE-50 polyethylene tubing (Clay Adams) was inserted into the left external carotid artery of rats that had just undergone angioplasty, such that it did not protrude into the lumen of the common carotid artery. This route of administration was chosen (1) to limit the degree of surgical manipulation and (2) because, relative to intravenous administration, intra-arterial endothelin-1 infusions produce less pronounced changes in systemic hemodynamics.13 By use of a Sage model 355 syringe pump (infusion rate, 150 gL/min, Orion Research), this arterial line was used for an acute 30-minute infusion of either endothelin-1 (5 to 500 pmol/kg) or saline vehicle (0.9% NaCl [wt/vol]). Once the infusion was complete, the PE-50 tubing was removed, and a suture was tied around the external carotid. Finally, the wound was closed using 9-mm Autoclips (Clay Adams), and the surgical area was swabbed with Povadyne surgical scrub (7.5% povidone-iodine, Chaston). Animals were housed in Plexiglas cages under a 12-hour light/dark cycle with access to standard laboratory chow and drinking water ad libitum. Common carotid arteries were removed from the animals after 7 days (treated with saline or 500 pmol/kg endothelin-1) or 14 days (treated with saline or 5 to 500 pmol/kg endothelin-1) for histological examination.
Histopathologic Examination
Neointimal formation was quantified in common carotid arteries removed from rats after in situ perfusion fixation (90 mm Hg) using 10% (wt/vol) phosphate-buffered formalin (Baxter Scientific Products). After standard histological processing, three arterial cross sections (6 gm) were cut from paraffin blocks containing the middle third of these arteries, which were then stained with Giemsa. The neointimal and medial cross-sectional areas of these vessels were quantified by use of a Bioscan Optimus cell-imaging system.
Hemodynamic Effects of Acute Administration of Endothelin-1
In a separate series of experiments, the systemic hemodynamic effects of intra-arterial endothelin-1 administration immediately after balloon angioplasty were determined. Male Sprague-Dawley rats (350 to 450 g) were anesthetized with sodium pentobarbital (65 mg/kg IP), allowing cannulation of the right femoral artery (PE-50 tubing) for continuous measurement of systemic arterial blood pressure with a miniature Gould P231D pressure transducer (Grass Instrument Co) linked to a Grass model 79D polygraph; this signal was used to derive mean arterial pressure and heart rate. Left common carotid arterial blood flow was monitored by placing a 1R series Transonics perivascular flow probe around the vessel (Transonics Systems Inc). The probe was linked to the polygraph via a T206 Transonics blood flow monitor, allowing continuous recording of carotid arterial blood flow and vascular resistance. Hemodynamic parameters were recorded in animals before and after left common carotid artery balloon angioplasty. Immediately after angioplasty, either endothelin-1 (5 to 500 pmol/kg over 30 minutes) or saline was infused, as detailed above. Arterial blood samples were removed via the femoral artery 30 minutes later on completion of the endothelin-1 infusion for determination of plasma immunoreactive endothelin-1 levels by use of a double-antibody sandwich enzyme immunoassay (Cayman Chemical Co).14
Effect of SB 209670 on the Degree of Neointimal Formation
In a separate series of experiments, rats were pretreated either with SB 209670 (2.5 mg/kg IP, twice a day) or an equal volume of saline vehicle (1 mLlkg IP, twice a day) for 3 days before angioplasty. Treatment was continued for a subsequent 2 weeks after surgery, at which point the animals were killed, allowing carotid arteries to be removed for histological examination.
Statistics
All values are expressed as mean-+-SEM, and n represents the number of animals or triplicate experiments used in a particular group. Statistical comparisons were made by oneway ANOVA (Fisher's protected least-squares difference), and values were considered to be significant at P<.05.
Materials
Solutions of drugs and peptides were freshly made each day and stored on ice in a light-tight container throughout the duration of an experiment. Endothelin-1 (100 gmol/L stock solution in 0.5% bovine serum albumin [wt/vol]) was from American Peptide Co, Inc. 
Results
Effects of SB 209670 on [3H]Thymidine
Incorporation in Cultured Vascular Smooth Muscle Cells
Endothelin-1 (1 nmol/L) stimulated a ninefold increase in [3H]thymidine incorporation in rat aortic vascular (Fig 1) , did not alter 1 nmol/L [3H]thymidine incorporation induced by angiotensin 11 (5020±488 and 5060±470 cpm in the absence and presence of SB 209670, respectively), basic fibroblast growth factor (bFGF, 106 571±10 310 and 128970±20317 cpm in the absence and presence of SB 209670, respectively), or platelet-derived growth factor A/B (PDGF, 89 233+6912 and 66214±17507 cpm in the absence and presence of SB 209670, respectively) (all agonists, n=3). Similarly, basal [3H]thymidine incorporation was unaffected by SB 209670. Thus, SB 209670 did not appear to exhibit any nonspecific cytotoxicity, since 24-hour exposure of smooth muscle cells in culture to this compound did not alter basal or angiotensin Il-induced, bFGF-induced, or PDGF-induced [3H]thymidine incorporation or the ability to exclude trypan blue.
Effect of Acute Exogenous Endothelin-1 Administration on Neointimal Formation
Relative to saline-treated control rats, an acute intraarterial infusion of 500 pmol/kg endothelin-1 over a 30-minute period immediately after balloon angioplasty augmented the degree of catheter-induced neointimal formation when assessed 7 days later. The cross-sectional area of the tunica media was not significantly different between the two treatment groups (Fig 2a) ; however, the cross-sectional area of the neointima was 73% larger in the endothelin-1-treated group (Fig 2b) . This was in accord with a 53% increase in the neointima-to-media ratio (Fig 2c) . The morphometry of contralateral vessels isolated from endothelin-1-treated rats (medial and adventitial cross-sectional areas, 0.139±0.012 and 0.166±0.028 mm2, respectively; no neointima present; n=5) did not differ from those treated with saline (medial and adventitial cross-sectional area, 0.114+0.010 and 0.166±0.020 mm2, respec- tively; no neointima present; n=4). On the basis of the observation that 500 pmol/kg endothelin-1 augmented neointimal formation in vessels removed 7 days after surgery, it was demonstrated subsequently that the potentiating action of this peptide on neointimal formation was dose dependent (Fig 3A through 3H) in vessels isolated from animals that had undergone experimentation 14 days earlier. Indeed, a significant effect was observed with a lower dose of 50 pmol/kg endothelin-1.
Relative to saline-treated animals (14.3+2.3 pmol/L, n=5), the 500-pmol/kg dose of endothelin-1 caused a 20-fold increase in systemic plasma levels of endothelin-1 (309.9+64.8 pmol/L, n=5) at the end of the 30-minute infusion period. In contrast, 50 pmol/kg did not cause a significant increase in plasma levels of endothelin-1 (6.0±2.8 pmol/L, n=5). Compared with saline-treated rats, endothelin-1 administration did not alter the cross-sectional area of the media but enhanced the cross-sectional area of the neointima (Table) , resulting in a significantly augmented neointima-to-media ratio (Fig 3) . At the highest dose of endothelin-1 studied (500 pmol/kg), the cross-sectional area of the neointima and the neointima-to-media ratio were increased by 151% and 115%, respectively. Morphologically, the lesions from endothelin- vessels and were histologically indistinguishable from control vessels. An intact endothelium was observed in vessels from both saline-treated and endothelin-1treated groups.
Hemodynamic Effects Associated With Acute Intra-arterial Endothelin-1 Administration
The acute hemodynamic effects of the intra-arterial infusions of endothelin-1 were assessed in rats under similar conditions immediately after angioplasty. During the 30-minute infusion period, angioplasty followed by saline infusion resulted in a transient decrease in mean arterial pressure, which returned to control levels within 15 minutes (Fig 4a) . Endothelin-1 administration was devoid of systemic pressor activity at all doses studied, and as was seen in control rats, moderate hypotension was also observed. Similar transient decreases in heart rate were also observed in response to saline infusion (Fig 4b) . However, this response was more exaggerated in rats receiving endothelin-1: 500 pmol/kg endothelin-1 resulted in a significant bradycardia of 50 beats per minute (P<.001, Fig 4) . The most profound effect associated with the endothelin-1 infusion was a sustained decrease in carotid artery blood flow (Fig 4c) . Although blood flow was also reduced in control animals by ;75% during the first 15 minutes of the infusion period, this effect was transient, returning to basal levels within 20 minutes. Since mean arterial pressure was not elevated, this decrease in blood flow resulted from an increase in resistance in the left common carotid vascular bed downstream from the injured section of artery (Fig 4d) . Relative to salinetreated rats, acute intra-arterial infusion of 500 pmol/kg endothelin-1 caused a significant decrease in left carotid blood flow (P<.05, Fig 4) in addition to significant bradycardia. The changes in mean arterial pressure and left carotid vascular resistance were not different from those observed in animals receiving saline vehicle. Similarly, the hemodynamic changes observed with 5 and 50 pmol/kg endothelin-1 were not significantly different from those observed in vehicle-treated rats.
Effect of SB 209670 Administration on Neointimal Formation After Balloon Angioplasty
Administration of SB 209670 reduced neointimal lesion plasty (Fig 5A through 5D) . Treatment with SB 209670 (2.5 mg/kg IP, twice a day) did not alter the cross section of the tunica media (0.145±0.008 and 0.151±0.011 mm2 in control [n=9] and SB 209670-treated [n=7] rats, respectively). However, neointimal cross-sectional area was attenuated (53% decrease: control rats, 0.120±0.027 mm2; SB 209670 rats, 0.064±0.017 mm2) by SB 209670, and when the degree of lesion formation was expressed as a ratio between neointimal and medial cross-sectional areas, this inhibition (47% decrease) was significant ( Fig SE) . An intact endothelium was observed in vessels from both treatment groups. As with vehicle-treated rats, all rats treated with SB 209670 appeared to be healthy on gross physical examination, and there were no differences in the changes in body weight between both vehicle-treated and SB 209670-treated rats throughout the duration of the study, indicating that the inhibitory effect was unlikely to result from nonspecific cytotoxicity (324±3 g before vehicle treatment, increasing to 391±4 g 14 days after surgery [n=9]; 322+5 g before SB 209670 treatment, increasing to 407±7 g 14 days after surgery [n=7]). The lesions observed in saline-treated and SB 209670-treated rats differed only in size; no histological differences were noted between the two groups. Contralateral right common carotid arteries from both groups of rats were morphologically identical, both being normal in appearance and devoid of neointima.
Discussion
In the present study, endothelin-1 stimulated ['H]thymidine incorporation in cultured rat aortic vascular smooth muscle cells. This response was inhibited by SB 209670, a rationally designed nonpeptide endothelin receptor antagonist.'1 This effect did not result from nonselective cytotoxicity, since SB 209670 did not inhibit either basal [3H]thymidine incorporation or that stimulated by either angiotensin II, bFGF, or PDGF. Similarly, SB 209670 did not alter the ability of cells to exclude trypan blue, an index of cellular viability. Previous studies have demonstrated that cultured rat and human vascular smooth muscle proliferation, as assessed by [3H]thymidine incorporation and increased cell count, is mediated by the ETA receptor subtype.3.5"15 This finding is supported by the present study, in which IC50 of SB 209670 for the inhibition of endothelin-1-induced [3H]thymidine incorporation (6.2±2.2 nmol/L) was found to be similar to its Kb at the ETA receptor (~0.4 nmol/L compared with a Kb of 50 nmol/L at the ETB receptor).1" Since endothelin-1 levels are acutely elevated in the human coronary sinus after PTCA, it has been postulated that enhanced exposure of the underlying smooth muscle to endothelin-1, either derived from the circulation or released by damaged endothelial cells or smooth muscle cells at or adjacent to the lesion, may facilitate neointimal formation. Indeed, such an action may be exacerbated at the site of endothelium denudation, where the agonist-induced release of antiproliferative factors, such as nitric oxide or prostacyclin, may be absent.3"16 However, a causal relation for endothelin-1 in restenosis after angioplasty has not been established: clinical observations only implicate endothelin-1 indirectly, and the extrapolation of results from cell culture to an integrated in vivo system may be misleading (eg, because of the absence of blood-borne factors and interformation in the rat carotid artery after balloon angioactions between the smooth muscle cells and additional n=6) endothelin-1 on mean arterial blood pressure (a), heart rate (b), and left common carotid blood flow (c) and vascular resistance (d). The infusion period, indicated by the hatched bar, was initiated immediately after completion of the angioplasty procedure (t=0 minutes). The arrow indicates the point at which the left external carotid artery was ligated (t= -15 minutes) before balloon insertion. Results are expressed as mean+SEM, and n represents the number of rats in each group. Relative to saline-treated rats, intra-arterial infusions of either 5 or 50 pmol/kg endothelin-1 did not result in significant changes in mean arterial pressure, heart rate, or left carotid blood flow and vascular resistance (by AVOVA and Fisher's protected least-squares difference). Similarly, when compared with saline-treated rats, intra-arterial infusion of the highest dose of endothelin-1 (500 pmol/kg) did not significantly alter the changes in mean arterial pressure and left carotid vascular resistance. However, in rats that received 500 pmol/kg endothelin-1, heart rate and left carotid artery blood flow were significantly reduced relative to saline-treated rats (P<.001 and P<.05, respectively, by AVOVA and Fisher's protected least-squares difference). cell types). Therefore, the present study assessed the pathogenic role of endothelin-1 in balloon catheterinduced rat carotid artery lesion formation.
Acutely exposing the damaged carotid artery to exogenously administered endothelin-1 augmented the degree of intimal lesion formation, an effect limited to the damaged vessels, since the morphology of contralateral carotid arteries was unaltered by endothelin-1 administration. The potentiation induced with 500 pmol/kg, associated with a 20-fold increase in plasma endothelin-1 levels, was observed as early as 1 week after surgery. Indeed, significant effects could be observed in day-14 vessels with 50 pmol/kg endothelin-1, a dose of peptide that did significantly alter the systemic hemodynamics or circulating levels of peptide. Under control conditions, lesion formation in this model is almost maximal 14 days after angioplasty (--85% of the maximal response).16 Therefore, since lesion size was more than doubled by 500 pmol/kg endothelin-1 in day-14 vessels, endothelin-1 appeared to increase the extent rather than simply to enhance the rate of lesion formation.
However, such findings do not establish a definitive cause-effect relation between the in vitro smooth muscle mitogenic actions of endothelin-1 and the ability to promote neointimal formation in the intact rat. Indeed, several alternative mechanisms to enhanced smooth muscle proliferation may exist to explain the enhanced neointimal formation observed after acute endothelin-1 administration. Since endothelin-1 does not promote extracellular matrix production in cultured smooth muscle cells or stimulate endothelial cell migration, such mechanisms appear unlikely (although they cannot be entirely excluded).10,17 However, endothelin-1 induces the expression and release of several pharmacologically diverse growth factors (eg, PDGF and transforming growth factor-fl) in vitro with which it is able to synergize.39,10 Therefore, endothelin-1 may function as an indirect comitogen in this animal model. A change in shear stress is another recognized stimulus for smooth muscle proliferation. Indeed, it has been reported that increases in blood flow produced after arteriovenous fistula formation inhibit neointimal hyperplasia in porous polytetrafluoroethylene grafts implanted in the arterial circulation of baboons.'s However, although hemodynamic studies demonstrated that 500 pmol/kg endothelin-1 significantly decreased left common carotid artery blood flow (by :-75% as a consequence of transient systemic vasodepression and an increased carotid vascular resistance), no significant change in flow was observed with the 50 pmol/kg dose of endothelin-1, a dose that did cause a significant increase in the neointima-to-media ratio. Clearly, the present study does not resolve the mechanism that underlies the phenomenon whereby endothelin-1 administration augments neointimal formation. This requires further detailed investigation.
The increases in neointimal size obtained in vivo in response to the administration of endothelin-1 are interesting in light of the extremely short plasma halflife of this peptide (;1 minute).19 However, unlike other circulating hormones, such as angiotensin II and norepinephrine, the potent vascular actions of endothelin-1 are extremely prolonged.3 Indeed, endothelin-1 binds to its receptor in a pseudo-irreversible fashion, where the half-life for ligand-receptor dissociation is in excess of 100 hours. 20 Thus, although the changes in endothelin-1 levels that occur in the human coronary sinus after angioplasty or in the present study are likely to be of a similarly acute nature (although the latter was not studied), the exaggerated binding kinetics and pharmacodynamic effects of endothelin-1 may mean that a prolonged exposure to the peptide is unnecessary to produce profound effects on neointimal formation. In this respect, endothelin-1 may differ from other neurohumoral factors such as angiotensin II (only prolonged exposure to circulating levels of such factors have been reported to enhance neointimal formation, ie, sustained 2-week exposure to hypertensive levels of angiotensin II that were also associated with increased medial area in both injured and uninjured vessels). 21 During the initial stages of lesion formation, the endothelium (the primary tissue responsible for endothelin-1 synthesis) is absent as a result of angioplasty. However, in addition to the endothelium, cultured rat vascular smooth muscle cells also synthesize endothelin-1 after, for example, exposure to angiotensin II.111 Therefore, subsequent to denudation of the endothelium, the smooth muscle cells may act as an additional source of endothelin-1 present in the blood vessel wall to complement that derived from the circulation or from damaged endothelial cells proximal to the lesion site.
The results obtained with chronic administration of SB 209670 in this model, where the neointimal area observed 14 days after balloon angioplasty was reduced by :50%, directly implicates endothelin-1 in the pathogenesis of neointimal formation in the rat carotid artery. Gross physical examination of the rats used in the Treatment group present study indicated that SB 209670 was well tolerated by the animals; eg, increases in body weight were identical between both groups of rats, and contralateral vessels from SB 209670-treated rats were not different from vessels from rats that had received saline vehicle, indicating that SB 209670 was not exerting any overt nonspecific cytotoxic effects. Therefore, the present study is the first demonstration of the efficacy of an endothelin receptor antagonist in an animal model of balloon angioplasty. However, before SB 209670 can be considered as a clinical candidate for adjunct therapy to PTCA, the efficacy of endothelin antagonists must be investigated in other animal models of neointimal formation in which more complex lesions and rigorous dosage regimens can be studied. The limitation of this model as a predictor of clinical efficacy demonstrates that caution must be exercised in extrapolating the data obtained in the angioplasty model to the clinical situation.1'2
